GEN PODCAST - weekly podcasts from Genetic Enginee

Tackling regulatory hurdles in biopharma can either be like an equestrian event, where rider and horse majestically bound over obstacles in their path or like bumper cars at a carnival where the driver is bounced off course by other vehicles they didn’t even see coming. While graceful trotting across the often-muddy regulatory grounds is the desired course, navigating hurdles doesn’t come naturally and requires a fair bit of training by instructors who have real experience. This is what the M Lab Collaboration Centers brings to the table when assisting clients with the best approaches for gamboling over regulatory barriers—especially in bourgeoning biopharma markets such as Asia. In this podcast, we will hear from two members of the Merck team stationed in the APAC region who will describe how the M Lab Collaboration Centers have been instrumental in training personnel to work with local regulatory agencies to move biotech companies forward. This is part four in the five-part podcast series tackling diverse issues such as next-generation bioprocessing, bioproduction training in emerging markets, cell and gene therapy manufacturing challenges, and viral safety assurance in upstream and downstream. Make sure you check back regularly to hear the latest GENcast session.   https://www.genengnews.com/wp-content/uploads/2019/03/Training-Podcast_Chinese-FDA_MERCK.mp3   Panelists: Miles Shi Associate Director, Asia Vaccine and Viral Therapies Segment Development Merck   Charles Park Manager, Manufacturing Science and Technology Merck       The post GENcast: Explore, Learn, and Collaborate on Regulatory Challenges in Asia appeared first on GEN - Genetic Engineering and Biotechnology News.

Advancing Gene Therapy

New York City Goes for Biotech Gold

Transforming the Bioresearch and Healthcare Industries

Inhibiting Cancer Metastasis

New Method Developed for Growing Tissue Engineered Corneas

Millipore Says It is Bullish on Continuous Bioprocessing

New Drug Delivery Materials May Help Patient Compliance with Meds

Looking at the CAR-T Landscape As First Approval Nears

SARS and MERS Inhibited by Ebola Drug

Bioengineers Use Quantum Dots to Help Develop New Therapies for Multiple Sclerosis

Soft Tissue Synthetic Retina Created

FDA’s New Commissioner Hits the Ground Running

New Zika Test Shines LAMP in the Dark

Inflammation-Sensing Gut Bacteria Brought to You by Synthetic Biology

Look Beyond the Lab For That Next Job

Four-Stranded DNA May Aid in Developing Targeted Cancer Therapies

Feed a Cold, Starve a Fever: Old World Wisdom Still Holds True

BIO 2013 Session Preview: “Behind the Tech Transfer Headlines”

Podcast Title: Is It Worth It? Assessing the Value of Targeted Therapeutics and Companion Diagnostics.